Enesi Pharma, a biotechnology company developing next-generation vaccination products targeting serious diseases, has partnered with the University of Adelaide to develop a new thermostable, solid dose DNA vaccine for Zika virus to prevent infection of pregnant women and the resultant congenital effects in the unborn child.   This project aims to employ Enesi’s ImplaVax formulation expertise and platform to create a protective Zika virus DNA vaccine in a solid dose implant format for trans...